RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00034915.xml
PDF herunterladen
Onkologische Welt 2018; 09(04): 159-162
DOI: 10.1055/s-0038-1670942
DOI: 10.1055/s-0038-1670942
Hämato-Onkologie: EMN 2018
Neue Therapieoptionen für die rezidivierte/refraktäre Erkrankung
Multiples MyelomWeitere Informationen
Publikationsverlauf
Publikationsdatum:
10. September 2018 (online)
Zusammenfassung
Die erste Jahresversammlung des European Myeloma Network (EMN) versammelte 600 Teilnehmer aus ganz Europa, um über die Fortschritte in der Therapie des multiplen Myeloms (MM) zu diskutieren. In einer Sitzung zum rezidivierten und refraktären Myelom wurden neue Therapieoptionen und der optimale Zeitpunkt und Patienten-selektion für den Einsatz aufgezeigt.
MissingLinkText
MissingLinkText
-
Literatur
- 1 Moreau P. et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.. Ann Oncol 2017; 28: iv52-iv61
- 2 Mateos MV. et al. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: Updated analysis of CASTOR. ASH. 2016. Abstract 1150
- 3 Mateos MV. et al. Relapsed or refractory multiple myeloma patients treated with second-line carfilzomib and categorized by prior exposure to bortezomib: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. ASH. 2017. Abstract 1840
- 4 Ocio EM. et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.. Leukemia 2015; 29: 705-714
- 5 Paludo J. et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomiderefractory multiple myeloma.. Blood 2017; 130: 1198-1204
- 6 Dimopoulos MA. et al. Elotuzumab plus lenalidomide/ dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.. Br J Haematol 2017; 178: 896-905
- 7 Van Beurden-Tan CHY. et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma.. J Clin Oncol 2017; 35: 1312-1319
- 8 Van de Donk NWCJ. et al. CD38 antibodies in multiple myeloma: Back to the future.. Blood 2018; 131: 13-29
- 9 Rodrigues-Otero P. et al. Pembrolizumab plus lenalidomide and low-dose dexamethasone for patients with relapsed/refractory multiple myeloma: Efficacy and biomarker results from the phase 1 KEYNOTE-023 study. EHA. 2017. Abstract S783
- 10 Badros A. et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.. Blood 2017; 130: 1189-1197
- 11 FDA Safety communication vom 31. August 2017. Im Internet unter https://www.fda.gov/Drugs/ DrugSafety/ucm574305.htm
-
Literatur
- 1 Moreau P. et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.. Ann Oncol 2017; 28: iv52-iv61
- 2 Mateos MV. et al. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: Updated analysis of CASTOR. ASH. 2016. Abstract 1150
- 3 Mateos MV. et al. Relapsed or refractory multiple myeloma patients treated with second-line carfilzomib and categorized by prior exposure to bortezomib: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. ASH. 2017. Abstract 1840
- 4 Ocio EM. et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.. Leukemia 2015; 29: 705-714
- 5 Paludo J. et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomiderefractory multiple myeloma.. Blood 2017; 130: 1198-1204
- 6 Dimopoulos MA. et al. Elotuzumab plus lenalidomide/ dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.. Br J Haematol 2017; 178: 896-905
- 7 Van Beurden-Tan CHY. et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma.. J Clin Oncol 2017; 35: 1312-1319
- 8 Van de Donk NWCJ. et al. CD38 antibodies in multiple myeloma: Back to the future.. Blood 2018; 131: 13-29
- 9 Rodrigues-Otero P. et al. Pembrolizumab plus lenalidomide and low-dose dexamethasone for patients with relapsed/refractory multiple myeloma: Efficacy and biomarker results from the phase 1 KEYNOTE-023 study. EHA. 2017. Abstract S783
- 10 Badros A. et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.. Blood 2017; 130: 1189-1197
- 11 FDA Safety communication vom 31. August 2017. Im Internet unter https://www.fda.gov/Drugs/ DrugSafety/ucm574305.htm